Blitzima®
ACTIVE PRINCIPLE:
rituximab
INDICATION:
Non-Hodgkin lymphoma
b-cell chronic lymphocytic leukemia
DATE:
13/07/2017
STATUS:
Authorized
ACTIVE PRINCIPLE:
rituximab
INDICATION:
Non-Hodgkin lymphoma
b-cell chronic lymphocytic leukemia
DATE:
13/07/2017
STATUS:
Authorized